Effects of risedronate sodium on serum BGP and urine NTX/Cr in patients with postmenopausal osteoporosis
AIM:To study the effects of Risedronate Sodium Capsules on serum BGP and urine NTX/Cr in patients with postm-enopausal osteoporosis(PMOP). METHODS: One hundred and twenty pairs of postmenopausal women with low bone mineral density( BMD) were randomly classified into 2 groups. Group A (n = 120) were treated by risedronate sodium,5 mg,q. d with calcium 0.5 g and vitamin D200 IU,q. d. and Group B(n = 120) received the same treatment as that in group A except that placebo was given instead of risedronate sodium. The duration of the study was set to 12 months. Serum bone gla protein (BGP) and urine cross - linked N-telopeptide of collagen typeⅠ/creatine( NTX/Cr) were determined before as well as 6 and 12 months after the treatment by radioimmunoassay ( RIA) and enzyme-linked immunosor-bent assay ( ELBA). RESULTS: At the end of the treatment,BGP decreased by(2.9±4.7) and(0.5±3.9) μg/L respectively in group A and group B. In group A,NTX(nmol/L)/Cr (mmol/L) decreased by(9.4 ±65.9) but increased by(3. 6 ± 59. 9) in group B. There was statistical difference in BGP and NTX/Cr between the 2 groups. CONCLUSION: Risedronate sodium inhibits bone absorption and decreases bone turnover in women with postmenopausal osteoporosis.
NETL
NSTL
万方数据
维普
